Human Impact
Human Impact
OVERVIEW
MBC BioLabs companies have kicked off 214 FDA trials and wrapped up half of them.
214
Total Clinical Trials Started
102
Total Clinical Trials Completed
13,954
Total Enrolled Patients
13,954
Total Enrolled Patients
RECENT TRIALS
Recently Completed Trials
NOTABLE ALUMNI
Star Alumni
CASE STUDY
Lab-cultivated sushi-grade salmon
CONTEXT
• Secure U.S. regulatory clearance
• Focus on premium sushi market
• Prepare for U.S. product launch
EXECUTION
• Scaling fermentation-like production
• Backing via Cargill and celebrities
• Launching in elite restaurants
OUTCOMES
• FDA ‘no questions’ in May 2025
• $120M+ raised to-date
• 1st commercialized cultivated seafood
NEXT UP
• Multi-restaurant in Q3–Q4 ‘25
• Retail push in 2026
• Drive price-parity roadmap
CASE STUDY
Treating allergic disease before it starts
CONTEXT
• Reprograms microbiome
• Reduces early-life inflammation
• Prevents allergic diseases
EXECUTION
• Proven platform supports innovative pipeline
• Oral precision microbial consortia
• STMC-103H Ph 2 follow-up
OUTCOMES
• Earned FDA Fast Track designation
• Ph 2 showed positive topline ‘25
• 2026 readout momentum
NEXT UP
• New strategic partnerships
• Prep for pivotal development
• Expand platform indications
CASE STUDY
Non-opioid approaches to pain
CONTEXT
• Target peripheral sodium channels
• Associated with chronic pain
STRATEGY
• Developing oral pain medicines
• Blocks NaV1.8 and NaV1.7 targets
• Lowers addiction risks
OUTCOMES
• $100M Series C
• Eli Lilly M&A worth up to $1B
NEXT UP
• Lilly to integrate SiteOne
• Focus across pain indications